Takeda Continues Push Into Vaccines | Chemical & Engineering News
Volume 91 Issue 19 | p. 25 | Concentrates
Issue Date: May 13, 2013

Takeda Continues Push Into Vaccines

Department: Business
Keywords: vaccines, dengue fever, Japan

Japan’s Takeda Pharmaceutical has agreed to acquire Inviragen, a Fort Collins, Colo.-based vaccine developer, for $35 million plus future payments of up to $215 million. Inviragen’s lead candidate, now in Phase II clinical trials, is a four-strain recombinant viral vaccine for the prevention of dengue fever, a mosquito-borne illness. Building on a Japanese vaccine business, Takeda launched a global vaccine division in January 2012. Later that year it acquired LigoCyte Pharmaceuticals and its norovirus vaccine candidate.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment